Focus: Qilu Pharmaceutical is a 5,000+ employee Chinese generics and APIs manufacturer founded in 1958, headquartered in Jinan. The company operates across oncology, infectious diseases, immunology, neurology, and hematology with a pipeline spanning Phase 1–3 clinical programs.
Profile data last refreshed 13h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Qilu Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
ANDA generic in pre-launch phase; indication and clinical significance not provided in available data.
Help build intelligence for Qilu Pharmaceutical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Qilu Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
CDK4/6 inhibitor ANDA targeting ER+ breast cancer; mechanism well-established with cell-cycle arrest and apoptosis in xenograft models.
Proteasome inhibitor ANDA for relapsed/refractory multiple myeloma; demonstrated antiproliferative and proapoptotic activity in preclinical models.
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo